New study examines 2021 data by state, insurance type
Miami (June 24, 2025) - Prevalence of chronic obstructive pulmonary disease (COPD) and the disease's burden varies significantly by state. Understanding this variation could help address public health gaps to ease the burden on people with COPD and the health care system, according to a new study. The study is published in the March 2025 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal.
COPD is an inflammatory lung disease, comprising several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants like smoke or pollution. The COPD Foundation estimates that the disease (both diagnosed and undiagnosed cases) affects more than 30 million Americans. It is the fourth leading cause of death worldwide, according to the World Health Organization.
This new study used Medicare fee-for-service, Medicaid, and commercial health insurance claims data to examine COPD prevalence and burden by state and payer type. In 2021, approximately 11.7 million insured people had diagnosed COPD. The study found COPD prevalence at the state level varied widely, with West Virginia having the highest rate (143 per 1,000 insured individuals) and Utah having the lowest rate (44 per 1,000 insured individuals).
Read More
Digital inhalers can monitor changes in how much air is inhaled, duration of inhalation
Miami (June 17, 2025) - Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to a new study. The study is published in the May 2025 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal.
COPD is an inflammatory lung disease, comprising several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants like smoke or pollution. The disease affects more than 30 million Americans and is the fourth leading cause of death worldwide.
Exacerbations, or flare-ups, can cause accelerated loss of lung function, a decrease in quality of life, and reduce a person's physical function and activity. More than 50% of people with COPD experience at least one acute COPD exacerbation within four years of an initial COPD diagnosis. Increased respiratory rates and decreased lung volumes are early signs of an exacerbation.
Read More
Virtual programs allow for more personalized care
Miami (May 1, 2025) - Virtual pulmonary rehabilitation is a safe, effective alternative to traditional pulmonary rehabilitation programs for people with chronic obstructive pulmonary disease (COPD) who also require supplemental oxygen, according to a new report. The report is published in the March 2025 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal.
COPD is an inflammatory lung disease, comprising several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants like smoke or pollution. The disease affects more than 30 million Americans and is the fourth leading cause of death worldwide.
Pulmonary rehabilitation is an exercise and educational program supervised by a health care professional, which helps people with chronic breathing difficulties. These programs teach people how to manage their symptoms and improve their quality of life. Pulmonary rehabilitation programs are traditionally held in person; however, virtual or online programs are also available.
Read More
New study examines how perceived stress impacts respiratory health, other factors associated with COPD
Miami (April 29, 2025) - Increased perceived stress may cause worsened respiratory symptoms and decreased quality of life in people with chronic obstructive pulmonary disease (COPD), according to a new study. The study is published in the March 2025 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal.
Perceived stress is used to describe how overwhelmed or stressed a person feels based on their personal understanding of the situation. It is a psychosocial factor, along with loneliness, social isolation and emotional support, which have been shown to impact health outcomes in people with chronic diseases.
COPD is an inflammatory lung disease, comprising several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants like smoke or pollution. The disease affects more than 30 million Americans and is the fourth leading cause of death worldwide.
Read More
Patients and caregivers learn how to identify, manage worsening COPD
Miami (April 22, 2025) - The COPD Foundation is pleased to announce the completion of an educational campaign focused on managing advanced symptoms of chronic obstructive pulmonary disease (COPD), in partnership with Sanofi and Regeneron.
COPD comprises several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants like smoke or pollution. The disease affects more than 30 million Americans and is the fourth leading cause of death worldwide, yet awareness of the disease's symptoms, methods to reduce risk, and disease management remains poor. Symptoms include breathlessness, fatigue, and chronic cough.
The "Is This You?" campaign featured a website with information on how to recognize worsening symptoms of COPD, how to talk to health care providers, resources for caregivers, and information on Medicare; three blog posts; three educational podcasts; and two webinars.
Read More
Miami (April 3, 2025) - The COPD Foundation is extremely concerned with widespread reports of major staff reductions across the U.S. Department of Health and Human Services, including in the Food and Drug Administration's Center for Tobacco Products and the Centers for Disease Control's Office on Smoking and Health.
These resources are critical to addressing the public health crisis of lung disease in the United States, where 16 million Americans have been diagnosed with COPD and millions more remain undiagnosed. We urge elected officials to prioritize the health of Americans and ensure the ability of the U.S. Department of Health and Human Services to pursue that mission.
Read More
New study suggests statins protect chest muscles, while aspirin increases chest muscle loss
Miami (March 13, 2025) – For current and former smokers, statins may reduce the amount of chest muscle loss, while aspirin may contribute to increased chest muscle loss, according to a new study. The study is published in the January 2025 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal.
Many people who are current or former smokers are prescribed statins to manage high cholesterol and aspirin to manage heart disease. Research has shown that current or former smokers experience increased skeletal muscle loss, especially in people with COPD.
COPD is an inflammatory lung disease, comprising several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants like smoke or pollution. The disease affects more than 30 million Americans and is the fourth leading cause of death worldwide.
Read More
Network facilitates access to high-quality, specialized patient care for bronchiectasis and NTM lung disease
Miami (March 12, 2025) – The Bronchiectasis and NTM Association has accepted 27 Care Center and six Clinical Associate Center sites in 23 states and the District of Columbia into the new Bronchiectasis and NTM Care Center Network (CCN).
The CCN aims to facilitate access to specialized care and support for the hundreds of thousands of people with bronchiectasis and nontuberculous mycobacterial (NTM) lung disease.
“As the prevalence of bronchiectasis and NTM lung disease grows, it is even more important for us to create this Care Center Network to improve access to high-quality, specialty care and resources patients need,” said Doreen Addrizzo-Harris, M.D., Chair of the CCN Steering Committee. “The CCN’s innovative, nationwide network will help us achieve our goals of improving care and quality of life for those with these conditions, as well as advancing toward a cure.”
Read More
New study suggests people with arthritis should also be screened for COPD
Miami (March 11, 2025) - People with chronic obstructive pulmonary disease (COPD) and arthritis have a higher risk of death than people with arthritis who do not have COPD, according to a new study. The study is published in the January 2025 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal.
COPD is an inflammatory lung disease, comprising several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants like smoke or pollution. The disease affects more than 30 million Americans and is the fourth leading cause of death worldwide. Arthritis, or joint inflammation, is a leading cause of disability among American adults.
This new study analyzed data from more than 11,000 individuals in the United States from the National Health and Nutrition Examination Survey (NHANES) 1999-2018 who self-reported having arthritis. The study cohort included 1,795 participants with COPD and 9,503 without COPD.
Read More
New study highlights importance of diagnosing depression, anxiety to address gaps in care
Miami (March 6, 2025) - Mental health disorders in people with chronic obstructive pulmonary disease (COPD) are underdiagnosed and undertreated, leading to worsened symptoms and decreased quality of life, according to a new study. The study is published in the January 2025 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal.
COPD is an inflammatory lung disease, comprising several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants like smoke or pollution. The disease affects more than 30 million Americans and is the fourth leading cause of death worldwide.
Depression and anxiety are common comorbidities in people with COPD, which lead to increased symptom burden and decreased quality of life. Screening questionnaires often are used to detect symptoms of these disorders in people with COPD; however, these screening tools cannot be used definitively to confirm their diagnosis.
Read More
2025 marks the 10th anniversary of Leonard Nimoy's passing
Miami (February 27, 2025) - The COPD Foundation, The Nimoy Knight Foundation, and Health Point Productions today announce their partnership to distribute the documentary "Remembering Leonard Nimoy: His Life, Legacy and Battle with COPD."
Nimoy died in February 2015 at the age of 83 from complications related to severe chronic obstructive pulmonary disease (COPD). COPD comprises several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants like smoke or pollution.
The disease affects more than 30 million Americans and is the fourth leading cause of death worldwide, yet awareness of the disease's symptoms, methods to reduce risk, and disease management remains poor.
Read More
Miami (February 18, 2025) - Today, Bronchiectasis and NTM 360 announced a rebrand to become the Bronchiectasis and NTM Association. The rebranding reflects the organization's continued growth as a leader in advancing care, research, and awareness of bronchiectasis and nontuberculous mycobacterial (NTM) lung disease.
Bronchiectasis is a lesser-known chronic lung disease characterized by enlarged airways that are thickened and/or scarred. These permanently widened airways lead to a buildup of mucus and impaired clearance of bacteria from the lungs. Symptoms include frequent coughing with mucus, breathlessness, fatigue and unexplained fever and chills. It is estimated that more than 1 million people are diagnosed with bronchiectasis worldwide, and of those, 340,000 to 522,000 are adults in the United States.
NTM lung disease is characterized by recurring lung infections, causing significant damage to a person's airways. Symptoms can include cough, shortness of breath, fatigue, and weight loss. It is estimated that more than 200,000 people in the United States have NTM lung disease, with the number of new cases increasing 8% annually.
Read More